CLAIMS

1. A pharmaceutical composition for treating or preventing an allergic disease, comprising, as active ingredients, probiotics and a polypeptide with a binding ability to IgE,
wherein the probiotics is any one selected from the group consisting of *B. longum, L. casei, Lc. lactis, S. thermophilus, L. rhamnosus, L. reuteri,* and *L. fermentum,*
wherein the polypeptide with a binding ability to IgE is a polypeptide dimer containing two monomers, each of which contains an extracellular domain of an alpha subunit of an IgE Fc receptor (FcεRIαECD),
the monomer contains a modified Fc region, and
the modified Fc region and the FcεRIαECD are linked via a linker.

2. The pharmaceutical composition for treating or preventing an allergic disease according to claim 1,
wherein the extracellular domain of the alpha subunit of the IgE Fc receptor has the amino acid sequence of SEQ ID NO: 1.

3. The pharmaceutical composition for treating or preventing an allergic disease according to claim 1,
wherein the probiotics are in the form of a dried powder.

4. The pharmaceutical composition for treating or preventing an allergic disease according to claim 1,
wherein the allergic disease is any one selected from the group consisting of food allergy, atopic dermatitis, asthma, allergic rhinitis, allergic conjunctivitis, allergic dermatitis, chronic idiopathic urticaria, and allergic contact dermatitis.

5. A health functional food composition for ameliorating or alleviating an allergic symptom, comprising, as active ingredients, probiotics and a polypeptide with a binding ability to IgE,
wherein the probiotics is any one selected from the group consisting of *B. longum, L.*

casei, Lc. lactis, S. thermophilus, L. rhamnosus, L. reuteri, and *L. fermentum,*

wherein the polypeptide with a binding ability to IgE is a polypeptide dimer containing two monomers, each of which contains an extracellular domain of an alpha subunit of an IgE Fc receptor (FcεRIαECD),

the monomer contains a modified Fc region, and

the modified Fc region and the FcεRIαECD are linked via a linker.

6. A kit for treating or preventing an allergic disease, comprising:

a first composition that contains probiotics; and

a second composition that contains a polypeptide with a binding ability to IgE,

wherein the probiotics is any one selected from the group consisting of *B. longum, L. casei, Lc. lactis, S. thermophilus, L. rhamnosus, L. reuteri,* and *L. fermentum,*

wherein the polypeptide with a binding ability to IgE is a polypeptide dimer containing two monomers, each of which contains an extracellular domain of an alpha subunit of an IgE Fc receptor (FcεRIαECD),

the monomer contains a modified Fc region, and

the modified Fc region and the FcεRIαECD are linked via a linker.

7. The kit for treating or preventing an allergic disease according to claim 18,

wherein the second composition is a composition for subcutaneous or intravenous administration.